Eris Lifesciences

What Eris Lifesciences does

Eris Lifesciences is an India-focused, publicly listed pharmaceutical company (NSE: ERIS) headquartered in Ahmedabad that develops, manufactures, and commercializes branded formulations in chronic and lifestyle disease segments, principally anti-diabetes, cardiovascular, dermatology, and women's health. Its commercial platform rests on a 1,200-Medical-Representative field sales force covering 87% of India's Rs 55,000-crore chronic therapy market, supported by wholly-owned subsidiaries Oaknet Healthcare (dermatology and cosmetology), Swiss Parenterals (EU-GMP compliant injectable manufacturing and CDMO), and the recently acquired Velbiom Probiotics prescription business.

The company monetizes primarily through domestic branded formulation sales (DBF), with a secondary CDMO revenue stream contributing 11% of FY26 revenue via Swiss Parenterals. Recent product economics are anchored by the March 2026 launch of generic semaglutide ('Sundae') at approximately $13.8-$14 per month, ~90% below branded Ozempic, marketed in partnership with Natco Pharma; the broader portfolio spans insulins (16% market share, up from 12% in April 2025), oral anti-diabetics (6% share, top-5), and dermatology products licensed from Caring Brands and distributed into LATAM, Russia, and Australia/New Zealand.

FY26 reported revenue of Rs 3,114.89 crore with a 36.2% EBITDA margin and net profit of Rs 619.52 crore (+76% YoY), alongside active inorganic expansion (Swiss Parenterals full ownership for Rs 423.3 crore, Velbiom for Rs 50 crore) and a declared FY27 interim dividend, position Eris as a profitable, cash-generative chronic-therapy franchise; key risks include a March 2026 HALMED GMP non-compliance finding at Swiss Parenterals and prior litigation around pioglitazone FDC bans.

Name

Eris Lifesciences

Legal name

Eris Lifesciences Limited

Website

https://eris.co.in

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Eris Lifesciences is an India-focused branded pharmaceutical company that develops and commercializes chronic and lifestyle disease formulations, including anti-diabetes, dermatology, and women's health products, via a 1,200-MR field force serving prescribers across India.

Ownership category

akta.pro rank

Product category

Pharmaceuticals (Chronic Disease Formulations)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA) (HLAGAKAJ)

Keywords

• Chronic disease pharmaceuticals
• Anti-diabetes medications
• Dermatology formulations
• Injectable manufacturing CDMO
• Branded generic drugs

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Supply Chain, Operations, Technology or R&D

Revenue model

1. Domestic Branded Formulations (DBF): Core revenue stream from branded pharmaceutical formulations sold in the Indian domestic market, covering chronic therapies including anti-diabetes, cardiovascular, dermatology, and women's health. The DBF segment delivered 12% revenue growth to ₹671 crore in Q4 FY26 with 37% EBITDA margin.
2. International Business / CDMO: International business including contract development and manufacturing (CDMO) services through Swiss Parenterals subsidiary, contributing 11% to FY26 revenue. Operations include EU-GMP compliant injectable manufacturing facilities.
3. Generic Semaglutide (Sundae): Revenue from generic semaglutide product launched following patent expiry, priced at approximately $13.8-$14 per month, targeting India's diabetes and weight management market.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels1 record

Core offering

Eris Lifesciences manufactures and markets branded pharmaceutical formulations focused on chronic and lifestyle disease segments in India, with a core portfolio in anti-diabetes, cardiovascular, dermatology, and women's health. The company operates a field force of 1,200 Medical Representatives and also provides EU-GMP compliant contract development and manufacturing (CDMO) of injectable formulations through its Swiss Parenterals subsidiary.

Differentiator

Problem solved

Functional benefit

Brands

• Sundae: Generic semaglutide brand for Type 2 diabetes and weight management launched in March 2026
• Generic Ozempic

Products and services

• Sundae (Generic Semaglutide) Generic GLP-1 receptor agonist (semaglutide) for Type 2 diabetes and weight management priced at approximately $13.8–$14 per month for the lowest dose, targeting India's diabetes and obesity patient population.
• Anti-diabetes and Metabolic Care Portfolio Branded pharmaceutical formulations for diabetes management, insulin therapy, cardiovascular conditions, and metabolic care sold across India, giving Eris a top-5 position in anti-diabetes and 16% market share in insulins.
• Oaknet Healthcare Dermatology Portfolio Dermatology and cosmetology branded formulations from Oaknet Healthcare covering skin disorders and cosmetic dermatology, distributed through Eris's nationwide dermatologist coverage.
• Swiss Parenterals Injectable CDMO Services EU-GMP compliant contract development and manufacturing of injectable formulations through Swiss Parenterals Units 1 (general liquid and dry powder injectables) and 2 (betalactam dry powder injectables) in Ahmedabad, Gujarat, serving international pharmaceutical clients.
• Velbiom Prescription Probiotics Prescription probiotic formulations with disease-specific, strain-specific, and site-specific indications for metabolic wellness and women's healthcare, strengthening Eris's specialty therapy portfolio.
• Women's Health Therapy Portfolio Branded pharmaceutical formulations for women's health and chronic therapy segments inherited from the Oaknet Healthcare acquisition.

Quantifiable outcome

• Q4 FY26 net profit grew 200.10% year-over-year to ₹281.61 crore
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• Natco PharmacoreStrategic or Co-development Partner · 24 February 2026Eris Lifesciences partnered with Natco Pharma to commercialize semaglutide in India. Natco received CDSCO approval for generic semaglutide on February 14, 2026, enabling launch in March 2026. The collaboration combines Eris's commercial infrastructure and diabetes franchise with Natco's manufacturing and regulatory capabilities in complex formulations for the GLP-1 receptor agonist market.
• Swiss Parenterals LtdcoreStrategic or Co-development Partner · 25 November 2025Eris Lifesciences acquired the remaining 30% stake in Swiss Parenterals for ₹423.3 crore, making Swiss a wholly-owned subsidiary. The share swap transaction is expected to finalize before March 31, 2026, consolidating injectable manufacturing operations.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Sun Pharmaceutical Industries: India's largest pharma company with a deep chronic-care and diabetes portfolio; directly competes with Eris in anti-diabetes and is now also launching generic semaglutide in India. Comparable on domestic branded formulations and emerging international CDMO ambitions.
• Cipla: Large Indian pharma with significant chronic and diabetes therapy presence plus a strong injectables/CDMO franchise; competes with Eris in domestic anti-diabetes and cardiovascular, and in injectable CDMO via its South African and Indian sites.
• Zydus Lifesciences (Cadila Healthcare): Diversified Indian pharma with strong diabetes, cardiology, and women's health franchises and an established injectable/biologics CDMO; competes across multiple Eris therapy areas and in GLP-1 generics.
• Lupin: Large Indian pharma with a significant chronic and diabetes portfolio plus complex injectables/CDMO; competes with Eris in domestic anti-diabetes and cardiovascular and has international CDMO exposure.

Direct peers

• Mankind Pharma: India-focused chronic and acute pharma with a leading field force and growing cardiometabolic/diabetes franchise; closely comparable on GTM model (large MR sales force) and domestic chronic positioning, and entering GLP-1 generics.
• Torrent Pharmaceuticals: Indian pharma focused on chronic and lifestyle therapies (cardiology, diabetes, CNS); comparable product mix, prescriber-focused sales model, and growing injectables footprint overlapping with Eris.
• Biocon: Indian biopharmaceutical company with leadership in insulins and biologics; directly comparable to Eris on insulin market dynamics and chronic diabetes franchise, and overlapping on injectable manufacturing.
• Natco Pharma: Strategic partner and Indian pharma with deep complex-generics and oncology expertise; supplies semaglutide API/formulation to Eris and competes in select chronic and oncology-adjacent segments.
• Glenmark Pharmaceuticals: Indian pharma with a chronic and specialty care focus (diabetes, dermatology, respiratory); directly comparable therapy mix and similar India-anchored field-sales GTM motion.
• Alkem Laboratories: Indian pharma with a sizable chronic and anti-infective franchise and growing domestic specialty presence; comparable in domestic branded formulations, field-force scale, and therapeutic-area focus on chronic care.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/ErisLS
• LinkedInlinkedin.com/company/eris-lifesciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eris Lifesciences